1887

Abstract

Piperine, a --isomer of 1-piperoyl-piperidine, was tested in combination with mupirocin for antimicrobial activity against strains including meticillin-resistant . The combination markedly reduced the MIC of mupirocin and also lowered the mutation frequency. Enhanced accumulation and efflux of ethidium bromide from wild-type and mutant (Mup-1) strains in the presence of piperine indicated that inhibition of efflux could be a possible mechanism of potentiation of mupirocin activity by piperine. The combination of piperine with mupirocin in a dermal infection model of mice showed better efficacy when compared with the commercially available formulation of 2 % mupirocin.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.033167-0
2011-10-01
2021-03-07
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/10/1472.html?itemId=/content/journal/jmm/10.1099/jmm.0.033167-0&mimeType=html&fmt=ahah

References

  1. Brenwald N. P., Gill M. J., Wise R. 1998; Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae . Antimicrob Agents Chemother 42:2032–2035[PubMed]
    [Google Scholar]
  2. CLSI 1998 Methods for Determining Bactericidal Activity of Antimicrobial Agents Approved Standard M26-A Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  3. CLSI 2008 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Approved Standard M7–A8 Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  4. Cookson B. D. 1998; The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 41:11–18 [CrossRef][PubMed]
    [Google Scholar]
  5. Diekema D. J., Pfaller M. A., Schmitz F. J., Smayevsky J., Bell J., Jones R. N., Beach M. the SENTRY Partcipants Group 2001; Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 32:Suppl. 2S114–S132 [CrossRef][PubMed]
    [Google Scholar]
  6. Drugeon H. B., Juvin M. E., Bryskier A. 1999; Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin. J Antimicrob Chemother 43:Suppl. C55–59 [CrossRef][PubMed]
    [Google Scholar]
  7. Eliopoulus G. M., Moellering R. C. J. 1996; Antimicrobial combinations. In Antibiotics in Laboratory Medicine, 4th edn. pp. 330–396 Edited by Lorian V. Baltimore, MD: Williams & Wilkins;
    [Google Scholar]
  8. Grundmann H., Aires-de-Sousa M., Boyce J., Tiemersma E. 2006; Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368:874–885 [CrossRef][PubMed]
    [Google Scholar]
  9. Huang J. O., O’Toole P. W., Shen W., Amrine-Madsen H., Jiang X., Lobo N., Palmer L. M., Voelker L., Fan F. et al. 2004; Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus . Antimicrob Agents Chemother 48:909–917 [CrossRef][PubMed]
    [Google Scholar]
  10. Khan I. A., Mirza Z. M., Kumar A., Verma V., Qazi G. N. 2006; Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureus . Antimicrob Agents Chemother 50:810–812 [CrossRef][PubMed]
    [Google Scholar]
  11. Kumar A., Khan I. A., Koul S., Koul J. L., Taneja S. C., Ali I., Ali F., Sharma S., Mirza Z. M. et al. 2008; Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus . J Antimicrob Chemother 61:1270–1276 [CrossRef][PubMed]
    [Google Scholar]
  12. Levy S. B. 1992; Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother 36:695–703[PubMed] [CrossRef]
    [Google Scholar]
  13. Levy S. B. 2002; Active efflux, a common mechanism for biocide and antibiotic resistance. J Appl Microbiol 92:Suppl.65S–71S [CrossRef][PubMed]
    [Google Scholar]
  14. Li X. Z., Nikaido H. 2004; Efflux-mediated drug resistance in bacteria. Drugs 64:159–204 [CrossRef][PubMed]
    [Google Scholar]
  15. Lomovskaya O., Bostian K. A. 2006; Practical applications and feasibility of efflux pump inhibitors in the clinic – a vision for applied use. Biochem Pharmacol 71:910–918 [CrossRef][PubMed]
    [Google Scholar]
  16. Nikaido H. 2001; Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin Cell Dev Biol 12:215–223 [CrossRef][PubMed]
    [Google Scholar]
  17. Perl T. M., Cullen J. J., Wenzel R. P., Zimmerman M. B., Pfaller M. A., Sheppard D., Twombley J., French P. P., Herwaldt L. A. the Mupirocin and the Risk of Staphylococcus aureus Study Team 2002; Intranasal mupirocin to prevent postoperative Staphylococcus aureus infection. N Engl J Med 346:1871–1877 [CrossRef][PubMed]
    [Google Scholar]
  18. Poole K. 2004; Efflux-mediated multiresistance in Gram-negative bacteria. Clin Microbiol Infect 10:12–26 [CrossRef][PubMed]
    [Google Scholar]
  19. Poole K., Lomovskaya O. 2006; Can efflux inhibitors really counter resistance?. Drug Discov Today Ther Strateg 3:145–152 [CrossRef]
    [Google Scholar]
  20. Poupard J. A. 1995; Update on mupirocin resistance. J Chemother 7:Suppl. 371–74[PubMed] [CrossRef]
    [Google Scholar]
  21. Rozen S., Skaletsky H. 2000; Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365–386[PubMed]
    [Google Scholar]
  22. Schmitz F. J., Fluit A. C., Lindenlauf E., Scheuring S., Köhrer K. 2000; Molecular analyses of possible mechanisms coding for low-level mupirocin resistance in clinical Staphylococcus aureus isolates. Eur J Clin Microbiol Infect Dis 19:649–650 [CrossRef][PubMed]
    [Google Scholar]
  23. Sharma S., Kumar M., Sharma S., Nargotra A., Koul S., Khan I. A. 2010; Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis . J Antimicrob Chemother 65:1694–1701 [CrossRef][PubMed]
    [Google Scholar]
  24. Wertheim H. F. L., Vos M. C., Ott A., van Belkum A., Voss A., Kluytmans J. A., van Keulen P. H., Vandenbroucke-Grauls C. M., Meester M. H., Verbrugh H. A. 2004; Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 364:703–705 [CrossRef][PubMed]
    [Google Scholar]
  25. Wertheim H. F. L., Melles D. C., Vos M. C., van Leeuwen W., van Belkum A., Verbrugh H. A., Nouwen J. L. 2005; The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5:751–762 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.033167-0
Loading
/content/journal/jmm/10.1099/jmm.0.033167-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error